Literature DB >> 24486361

Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen.

Celine A Hayden1, Emily M Smith1, Debra D Turner2, Todd K Keener1, Jeffrey C Wong3, John H Walker4, Ian R Tizard2, Rafael Jimenez-Flores5, John A Howard6.   

Abstract

The hepatitis B virus continues to be a major pathogen worldwide despite the availability of an effective parenteral vaccine for over 20 years. Orally-delivered subunit vaccines produced in maize may help to alleviate the disease burden by providing a low-cost, heat-stable alternative to the parenteral vaccine. Oral subunit vaccination has been an elusive goal due to the large amounts of antigen required to induce an immunologic response when administered through the digestive tract. Here we show that high levels of HBsAg were obtained in maize grain, the grain was formed into edible wafers, and wafers were fed to mice at a concentration of approximately 300 μg/g. When these wafers were made with supercritical fluid extraction (SFE)-treated maize material, robust IgG and IgA responses in sera were observed that were comparable to the injected commercial vaccine (Recombivax(®)). In addition, all mice administered SFE wafers showed high secretory IgA titers in fecal material whereas Recombivax(®) treated mice showed no detectable titer. Increased salivary IgA titers were also detected in SFE-fed mice but not in Recombivax(®) treated mice. Wafers made from hexane-treated or full fat maize material induced immunologic responses, but fecal titers were attenuated relative to those produced by SFE-treated wafers. These responses demonstrate the feasibility of using a two-dose oral vaccine booster in the absence of an adjuvant to induce immunologic responses in both sera and at mucosal surfaces, and highlight the potential limitations of using an exclusively parenteral dosing regime.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioencapsulation; HBsAg; Hepatitis B; Immunogenicity; Mucosal; Oral vaccine; Plant vaccine; Supercritical fluid extraction

Mesh:

Substances:

Year:  2014        PMID: 24486361      PMCID: PMC3999707          DOI: 10.1016/j.vaccine.2014.01.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization.

Authors:  S P Sellers; G S Clark; R E Sievers; J F Carpenter
Journal:  J Pharm Sci       Date:  2001-06       Impact factor: 3.534

2.  Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Authors:  Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2012-03-08       Impact factor: 3.641

3.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.

Authors:  J J Ott; G A Stevens; J Groeger; S T Wiersma
Journal:  Vaccine       Date:  2012-01-24       Impact factor: 3.641

4.  Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak.

Authors:  Roxanne E Williams; Arlene C Sena; Anne C Moorman; Zack S Moore; Umid M Sharapov; Jan Drobenuic; Dale J Hu; Hattie W Wood; Jian Xing; Philip R Spradling
Journal:  Vaccine       Date:  2012-03-13       Impact factor: 3.641

5.  Production of highly concentrated, heat-stable hepatitis B surface antigen in maize.

Authors:  Celine A Hayden; Erin M Egelkrout; Alessa M Moscoso; Cristina Enrique; Todd K Keener; Rafael Jimenez-Flores; Jeffrey C Wong; John A Howard
Journal:  Plant Biotechnol J       Date:  2012-07-21       Impact factor: 9.803

6.  Hepatitis A/B vaccine completion among homeless adults with history of incarceration.

Authors:  Adeline M Nyamathi; Elizabeth Marlow; Catherine Branson; Mary Marfisee; Karabi Nandy
Journal:  J Forensic Nurs       Date:  2012-01-06       Impact factor: 1.175

7.  Low hepatitis B vaccine response in children with Down syndrome from Brazil.

Authors:  R Nisihara; R S De Bem; P H R Negreiros; S R R Utiyama; N P Oliveira; H Amarante
Journal:  Child Care Health Dev       Date:  2013-08-19       Impact factor: 2.508

8.  Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men.

Authors:  D A MacKellar; L A Valleroy; G M Secura; W McFarland; D Shehan; W Ford; M LaLota; D D Celentano; B A Koblin; L V Torian; H Thiede; R S Janssen
Journal:  Am J Public Health       Date:  2001-06       Impact factor: 9.308

9.  Hepatitis A and hepatitis B infection prevalence and associated risk factors in men who have sex with men, Bangkok, 2006-2008.

Authors:  Robert W Linkins; Wannee Chonwattana; Timothy H Holtz; Punneeporn Wasinrapee; Supaporn Chaikummao; Anchalee Varangrat; Jaray Tongtoyai; Philip A Mock; Marcel E Curlin; Pachara Sirivongrangson; Frits van Griensven; Janet M McNicholl
Journal:  J Med Virol       Date:  2013-06-24       Impact factor: 2.327

10.  High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees.

Authors:  Angelique P A Vermeiren; Christian J P A Hoebe; Nicole H T M Dukers-Muijrers
Journal:  J Clin Virol       Date:  2013-07-26       Impact factor: 3.168

View more
  10 in total

1.  Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine.

Authors:  Shweta Shah; Celine A Hayden; Maria E Fischer; A Gururaj Rao; John A Howard
Journal:  Arch Biochem Biophys       Date:  2015-10-28       Impact factor: 4.013

2.  Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.

Authors:  Celine A Hayden; Chiung-Yu Hung; Hao Zhang; Austin Negron; Raymond Esquerra; Gary Ostroff; Ambily Abraham; Alejandro Gabriel Lopez; Juliet Elizabeth Gonzales; John A Howard
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

3.  Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.

Authors:  Celine A Hayden; Maria E Fischer; Bryan L Andrews; Hayley C Chilton; Debra D Turner; John H Walker; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2015-05-02       Impact factor: 3.641

Review 4.  Hepatitis B virus large surface protein: function and fame.

Authors:  Yuri Churin; Martin Roderfeld; Elke Roeb
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

Review 5.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

Review 6.  Corn-based vaccines: current status and prospects.

Authors:  Sergio Rosales-Mendoza; Cristhian Sández-Robledo; Bernardo Bañuelos-Hernández; Carlos Angulo
Journal:  Planta       Date:  2017-03-27       Impact factor: 4.116

Review 7.  In vitro plant tissue culture: means for production of biological active compounds.

Authors:  Claudia A Espinosa-Leal; César A Puente-Garza; Silverio García-Lara
Journal:  Planta       Date:  2018-05-07       Impact factor: 4.116

Review 8.  The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.

Authors:  Young Hee Joung; Se Hee Park; Ki-Beom Moon; Jae-Heung Jeon; Hye-Sun Cho; Hyun-Soon Kim
Journal:  Int J Mol Sci       Date:  2016-10-13       Impact factor: 5.923

9.  Micropropagation of transgenic lettuce containing HBsAg as a method of mass-scale production of standardised plant material for biofarming purposes.

Authors:  Tomasz Pniewski; Marcin Czyż; Katarzyna Wyrwa; Piotr Bociąg; Paweł Krajewski; Józef Kapusta
Journal:  Plant Cell Rep       Date:  2016-09-21       Impact factor: 4.570

Review 10.  Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development.

Authors:  Balamurugan Shanmugaraj; Ashwini Malla; Waranyoo Phoolcharoen
Journal:  Pathogens       Date:  2020-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.